Cargando…

Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report

OBJECTIVE: Current treatment agents for HCC are mostly immune checkpoint inhibitors (ICIs) plus bevacizumab and multitarget tyrosine kinase inhibitors (TKIs); however, their limited overall response rate and shorter median progression-free survival (PFS) discourage their frequent use. The developmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Ningning, Zhang, Ziheng, Guo, Sanxing, Shen, Shujing, Li, Xingya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244768/ https://www.ncbi.nlm.nih.gov/pubmed/37293311 http://dx.doi.org/10.3389/fmed.2023.1130012

Ejemplares similares

Corrigendum: Advanced HCC with amplified mesenchymal epithelial transition factor receptor responds well to savolitinib: a case report
por: Yan, Ningning, et al.
Publicado: (2023)

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
por: Yan, Ningning, et al.
Publicado: (2022)

Significant role of savolitinib in a case of advanced gastric cancer with abnormal mesenchymal‐epithelial transition factor (MET): A case report
por: He, XinCheng, et al.
Publicado: (2022)

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M
por: Wang, Yurong, et al.
Publicado: (2021)

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

SYNCRIP Modulates the Epithelial-Mesenchymal Transition in Hepatocytes and HCC Cells
por: Riccioni, Veronica, et al.
Publicado: (2022)

Savolitinib: A Promising Targeting Agent for Cancer
por: Lee, Tae Seung, et al.
Publicado: (2023)

Metformin reverses bFGF-induced epithelial-mesenchymal transition in HCC cells
por: Chengye, Wang, et al.
Publicado: (2017)

Lamp2 inhibits epithelial-mesenchymal transition by suppressing Snail expression in HCC
por: Zheng, Hao, et al.
Publicado: (2018)

HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway
por: Chen, Lu, et al.
Publicado: (2018)

Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
por: Yan, Ningning, et al.
Publicado: (2022)

Corrigendum: Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report
por: Yan, Ningning, et al.
Publicado: (2023)

Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model
por: Jones, Rhys D.O., et al.
Publicado: (2023)

Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib
por: Lim, Sun Min, et al.
Publicado: (2021)

Higher matrix stiffness as an independent initiator triggers epithelial-mesenchymal transition and facilitates HCC metastasis
por: Dong, Yinying, et al.
Publicado: (2019)

Immunocytochemical evaluation of epithelial–mesenchymal transition in epithelial tumors of dogs and cats
por: FURUSAWA, Yu, et al.
Publicado: (2021)

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition
por: Gu, Xuefeng, et al.
Publicado: (2019)

MiR-424-5p reversed epithelial-mesenchymal transition of anchorage-independent HCC cells by directly targeting ICAT and suppressed HCC progression
por: Zhang, Ying, et al.
Publicado: (2014)

Keratin 17 Suppresses Cell Proliferation and Epithelial-Mesenchymal Transition in Pancreatic Cancer
por: Zeng, Yong, et al.
Publicado: (2020)

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
por: Hartmaier, Ryan J., et al.
Publicado: (2023)

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:  Safety, Efficacy, and Biomarkers
por: Wang, Yakun, et al.
Publicado: (2022)

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
por: Lu, Shun, et al.
Publicado: (2022)

Catalpol Attenuates Pulmonary Fibrosis by Inhibiting Ang II/AT(1) and TGF-β/Smad-Mediated Epithelial Mesenchymal Transition
por: Yu, Qun, et al.
Publicado: (2022)

Epicardial epithelial-to-mesenchymal transition in injured heart
por: Zhou, Bin, et al.
Publicado: (2011)

Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and MET Abnormalities
por: Ye, Wen, et al.
Publicado: (2022)

Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C
por: Yoh, Kiyotaka, et al.
Publicado: (2021)

Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature review
por: Zhou, Kexun, et al.
Publicado: (2023)

P4HB promotes HCC tumorigenesis through downregulation of GRP78 and subsequent upregulation of epithelial-to-mesenchymal transition
por: Xia, Wei, et al.
Publicado: (2016)

High STRN Expression Promotes HCC Invasion and Migration but Not Cell Proliferation or Apoptosis through Facilitating Epithelial-Mesenchymal Transition
por: Du, Qian-yu, et al.
Publicado: (2020)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2023)

Chronic Hematuria Increases Chronic Kidney Injury and Epithelial–Mesenchymal Transition in 5/6 Nephrectomy Rats
por: Xiao, Min, et al.
Publicado: (2021)

Endothelial/Epithelial Mesenchymal Transition in Ascending Aortas of Patients With Bicuspid Aortic Valve
por: Maleki, Shohreh, et al.
Publicado: (2019)

Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review
por: Li, Linlin, et al.
Publicado: (2023)

Expression and prognostic significance of Golgiglycoprotein73 (GP73) with Epithelial-mesenchymal transition (EMT) related molecules in Hepatocellular Carcinoma (HCC)
por: Bao, Yong xing, et al.
Publicado: (2013)

MiR-4319 induced an inhibition of epithelial-mesenchymal transition and prevented cancer stemness of HCC through targeting FOXQ1
por: Han, Shaoshan, et al.
Publicado: (2019)

Type IIA topoisomerase (TOP2A) triggers epithelial-mesenchymal transition and facilitates HCC progression by regulating Snail expression
por: Dong, Yinying, et al.
Publicado: (2021)

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial
por: Kim, Seung Tae, et al.
Publicado: (2019)

Clinical evaluation of the potential drug–drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam
por: Ren, Song, et al.
Publicado: (2021)

Correlation of Bromodomain Protein BRD4 Expression With Epithelial–Mesenchymal Transition and Disease Severity in Chronic Rhinosinusitis With Nasal Polyps
por: Zhou, Xuanchen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t6797jim18il7hulsv1479f305